Robert Gadimian, President of Rophe Pharma Announces New Topical Hair Loss Solution

Los Angeles, CA, September 1, 2017 (Newswire.com) - ​​Robert Gadimian, owner of privately held Rophe Pharma, announced his company has been assigned product code RPHE-7193 for an exciting new treatment to fight hair loss. The treatment comes in the form of a topical solution using hydralazine. The background for hydralazine in RPHE-7193 is almost the same as minoxidil, the active substance in Minoxidil​. Hydralazine, like minoxidil, is a blood pressure drug that exhibited the side effect of promoting hair growth.

NEW HOPE FOR HAIR LOSS SUFFERERS

According to Gadimian, based on the preliminary results hydralazine is demonstrating to be a superior hair growth compound compared to minoxidil. In the exploratory study that is going on with 12 men, hair growth is being observed after 4-8 weeks of use in men up to age 65. The currently approved drugs for male pattern baldness (MPB) take a much longer time (6-12 months) to show their efficacy. So clearly there are men still hoping for more effective hair growth treatments such as RPHE-7193. The currently approved hair loss product have not been studied in men above age 41¹ but Gadimian is testing RPHE-7193 in that age group. Most of the men who suffer from hair loss are above age 41.

MINIMIZING SCALP IRRITATION

RPHE-7193 does not contain alcohol or polyethylene glycol, two solvents in other hair products that cause skin irritation and sensitivity; hence RPHE-7193 is formulated to avoid these skin related side effects.

ROPHE PHARMA'S NEW PRODUCT TO FIGHT HAIR LOSS

According to the America Hair Loss Association, MPB — also referred to as androgenetic alopecia — accounts for more than 95 percent of hair loss in men. By the age of 35, two-thirds of American men will experience some degree of appreciable hair loss; by the age of fifty, approximately 85 percent of men will contend with significantly thinning hair. Approximately 25 percent of men who suffer with MPB began the painful process of losing their hair before reaching the age of 21. For men unhappy with MPB, the effects can be wide-ranging and affect quality of life, both personal and professional. In spite of this widespread issue, no drug has been able to satisfactorily solve MPB in men. The available treatments take a long time to work. Minoxidil in its solution form has a few skin irritation side-effects and finasteride has some sexual side-effects for men.

AVOID FALSE PROMISES AND SEEK FDA APPROVED PRODUCTS

Minoxidil and finasteride currently constitute the only two FDA-approved drugs for hair loss treatment. Meanwhile, millions of hair loss sufferers remain eagerly poised for the introduction of legitimate and approved pharmaceutical drugs to expand their range of choices. This market demand has led to many fake treatments on the market. This has led the American Hair Loss Association to address questionable hair loss treatment therapies on the market and warn its members to use hair loss treatments that are approved by the FDA.

Gadimian announced that Rophe Pharma is planning to conduct the required studies by the FDA to get the product approved and to bring to market the desperately needed hair growth treatment that will work for most men in all age groups.

¹         Source: Summary basis of approval for Minoxidil​ and Finasteride ​

Source: Robert Gadimian